Publication
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerUveal Melanomacivic_curation1.00
- drugCabozantinibcivic_curation1.00
- geneGNA11civic_curation1.00
- geneGNAQcivic_curation1.00
- variantGNA11 Mutationcivic_curation1.00
- variantGNAQ Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28103611
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| GNA11 Mutation1 | ||||||||
| Cabozantinib | Uveal Melanoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID3049In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozanti… (full text at CIViC) PMID 28103611 · Daud et al., 2017 · Open in CIViC | civic |
| GNAQ Mutation1 | ||||||||
| Cabozantinib | Uveal Melanoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID5068Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib d… (full text at CIViC) PMID 28103611 · Daud et al., 2017 · Open in CIViC | civic |